Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a major pandemic. While vaccine development moves forward, optimal treatment continues to be explored. Efforts include an ever-expanding number of clinical trials along with newly proposed experimental and off-label investigational therapies; one of which is therapeutic plasma exchange (TPE). There have been a number of publications on TPE use as adjunctive therapy for coronavirus disease 2019 (COVID-19), but no prospective randomized controlled trials (RCTs) have been completed. This article critically appraises the current available evidence on TPE as a treatment modality for SARS-CoV-2 infection.
Original language | English (US) |
---|---|
Pages (from-to) | 483-491 |
Number of pages | 9 |
Journal | Journal of Clinical Apheresis |
Volume | 36 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2021 |
Keywords
- COVID-19
- SARS-CoV-2
- plasma exchange
ASJC Scopus subject areas
- Hematology